As FDA considers new Alzheimer’s drug, a case study details safety concerns
Sam Gandy, MD, PhD, discusses a new Alzheimer’s drug poised to be approved by U.S. regulators this week.
Tags:
Neurology,
Samuel E Gandy, MD, PhD

Press Release
Researchers Identify the Role of an Alzheimer’s Disease Risk Gene in the Brain
Nov 30, 2022 View All Press Releases